fbpix
Sale!

Alpha Male+PLUS

(1 customer review)

$40.99 $30.99

Alpha Male Plus – Ultimate Nutrition – For boosting Testosterone, Libido, Prostrate Cancer Prevention, Human Growth Hormone, Multivitamins, Nitric Oxide, Anti-Oxidants, Amino Acids, Omegas and Joint Support

SAFE & EASY TO USE – DISCREET – NO CALORIES OR SUGAR – GLUTEN FREE – NO FILLERS – NO COLORANTS – NO MESSY POWDERS.

Our patches are made from a material that is manufactured for sensitive skin, i.e. non-latex, non-plastic, non-woven Medical Grade Hypoallergenic adhesive.

6 Week Supply of 12 Patches. Use 2 Patches per week until you reach your desired results. Thereafter maintenance will be 1 Patch per Week.

Please note that due to US Dollar fluctuations, prices indicated are subject to change

READ MORE

 

SKU: SKU0009 Category:

Description

PHARMACOLOGICAL ACTION

As soon as the patch is applied, your body heat activates the time-release function of the transdermal patch and the supplement formula begins to transit through the skin for instant and constant delivery over a 72hour period. Time-release transdermal adhesives (patches) are the latest, most effective and most convenient way to absorb amino acids into your bloodstream.

COMPOSITION

Each patch contains: (New) Androsta-3,5-Diene-7, 17-Dione (Arimistane),  7-Hydroxyflavone, Eurycoma Longifolia Jack, D-Aspartic Acid, Stinging Nettle root,  Muira Pauma,  Furostanolic Saponins (from Fenugreek),  Forskolin (from Coleus Forskohlii), MK-677,  Ipamorelin, CJC-1295 (without DAC), Ornithine alpha ketoglutarate, GABA , L-Arginine, Nettle Leaf,  Cayenne, Orchic Substance,  Tribulus, Zinc, Sarsparilla,  Astragalus, Licorice Root, Pumpkin Seed,  Boron, Pygueum,  Maca , Horney Goat Weed,  Oatstraw , Catuaba, FoTi, Ginseng, Siberian Ginseng, Damiana, Gotu-Kola, Saw Palmetto, Menthol, Vitamin A as Retinol, Vitamin C as L-Ascorbic Acid, Vitamin D3 as cholecalciferol, Vitamin E as D-alpha-tocopheryl siccomate, Thiamin as thiamin mononitrate, Riboflavin, Niacin as niacinamide, Vitamin B6 as Pyridoxine HCI, Folic Acid, Vitamin B12 as Methylcobalamin, Biotin, Pantothenic Acid as D-Ca pantothenate, Inositol, Choline as choline bitartrate, Caratenoid Mix as alpha carotene, lutein, zeaxanthin, cyptoxanthin, Pyrroloquinoline quinone (PQQ), Resveratrol Trans Resveratrol, Astaxanthin, Ascorbate, Potassium iodide, IgG – Colostrum, 25 mg (milligrams) of GH produced by recombinant DNA technology (Somatropin), L-Arginine,  Xanthone,  Alpha-tocopherol, Anthocyanin, Glutathione, Lysine, Leucine, Phenylalanine, Valine, Isoleucine, Methionine, Threonine, Tryptophan, Tyrosine, Yohimbine, Noopept, Huperzine A, Vinpocetin, Hordenine, Glucosimine Sulfate, Chondroitin, Catyimeristoleate, Thiamine, Omega3, CoQ10, DHEA, DEHYDROLSOANDROSTERONE, PRASTERONE. MICRONIZED 100%, PREGNENOLONE.

Transdermal Patch Construction

  • Liner– Protects the patch during storage. The liner is removed prior to use.
  • Formula– Supplement or medication in direct contact with release liner
  • Adhesive– Serves to adhere the components of the patch together along with attaching the patch to the skin
  • Membrane– Controls the release of the medication or supplement from the reservoir and multi-layer patches
  • Backing– Protects the patch from the outer environment

DIRECTIONS FOR USE: Best locations on the body to apply Patches – The best locations to apply patches are where there are large concentrations of small blood vessels under the top skin (dermal) layers. The following illustration should be used as a general guide:

Technique – Firmly stick in place 1-3 Patches on clean skin and leave for 3 days. Apply to clean, dry and hair free skin.

Prepare Your Skin – To ensure comfort, decide where to apply the patch depending on your activities for the day. The best options for placement are the wrists and arms.

Apply the Patch – Remove the Patch from the packaging. Peel off the protective strip and immediately apply it to your skin. Press the Waterproof patch firmly to secure it in place. Do not remove for 3 days.  Please be sure to use clear waterproof tape (E.g. “Tegaderm”, “OPSITE FLEXIGRID or similar) over the Patch when swimming in Chlorinated water. This will serve to protect the active ingredients in the Patch. You may to bath with the patches on as normal tap water does not interfere with the active ingredients. Be careful not to rub aggressively over the Patch with soap as it may loosen the patch. Gently dry the wet Patch with an absorbent towel.

Patch Removal – Lift patch and peel away swiftly. Clean adhesive residue with some tissue oil (non-fragrant), and then wipe off with a damp cloth. Do not scratch or rub off adhesive as this may irritate sensitive skin.

Each patch is good for one use. Patch residue should be removed with soap and warm water.

 SIDE EFFECTS: There are no side effects with Homeopathic Transdermal DermaFusion Patches.

 WARNINGS: If you have serious health conditions or are taking medications, it is best to consult your physician before using the patch.

 CONTRA INDICATIONS: Do not ingest. Use only as directed by your Aesthetician.  If you are pregnant, nursing, taking any medications or have any medical condition, please consult your healthcare practitioner before taking any dietary supplement. Seek medical advice in the unlikely event of an adverse reaction. Only for Adult Use.  Do not use more than 3 patches in 24hrs. The Patch is not intended to diagnose, treat, cure or prevent any disease.

IDENTIFICATION: Each Pack contains 2 sets of 6 patches (12 Patches in total). Individual patches are 30mm X 30mm. Each patch has a cotton textured finish and is off-white in colour.

PRESENTATION: Globalderm Homeopathic Transdermal Derma Fusion Patches are hermetically sealed and housed in a Globalderm Branded box with the company LOGO. Each box is sealed with a Holographic Globalderm Security Sticker that is tamper proof to guarantee authenticity. BEWARE OF IMMITATIONS.

STORAGE

Store in a cool (at or below 25⁰ C), dry place and away from Sunlight, microwaves and computers. Homeopathic remedies last indefinitely. There is no shelf life / expiry date because they do not spoil or lose their potency if stored correctly. Homeopathic Transdermal Derma Fusion Patches must be stored in the packaging they come in, away from heat, direct sunlight, microwaves and computers. KEEP OUT OF REACH OF CHILDREN AND PETS.

References

Balon, Thomas W., and Jerry L. Nadler. “Evidence that nitric oxide increases glucose transport in skeletal muscle.” Journal of Applied Physiology 82.1 (1997): 359-363.

Barua, Rajat S., et al. “Dysfunctional endothelial nitric oxide biosynthesis in healthy smokers with impaired endothelium-dependent vasodilatation.” Circulation 104.16 (2001): 1905-1910.

Besco, Rauúl, et al. “The effect of nitric-oxide-related supplements on human performance.” Sports medicine 42.2 (2012): 99-117.

Bogdan, Christian. “Nitric oxide and the immune response.” Nature immunology 2.10 (2001): 907-916.

Bogdanski, P., et al. “Effect of 3-month L-arginine supplementation on insulin resistance and tumor necrosis factor activity in patients with visceral obesity.” Eur Rev Med Pharmacol Sci 16.6 (2012): 816-823.

Bryan, Nathan S. “The Importance of Nitric Oxide for Sexual and Exercise Performance and its Role in Adenosine Triphosphate Production.” Anti-Aging Therapeutics Volume XVI 16 (2015).

Burnett, Arthur L., et al. “Nitric oxide: a physiologic mediator of penile erection.” Science 257.5068 (1992): 401-403.

Cormio, Luigi, et al. “Oral L-citrulline supplementation improves erection hardness in men with mild erectile dysfunction.” Urology 77.1 (2011): 119-122.

Fu, Wenjiang J., et al. “Dietary L-arginine supplementation reduces fat mass in Zucker diabetic fatty rats.” The Journal of nutrition 135.4 (2005): 714-721.

Garthwaite, John. “Glutamate, nitric oxide and cell-cell signalling in the nervous system.” Trends in neurosciences 14.2 (1991): 60-67.

Haynes, William G., et al. “Inhibition of nitric oxide synthesis increases blood pressure in healthy humans.” Journal of hypertension 11.12 (1993): 1375-1380.

Jungersten, Lennart, et al. “Both physical fitness and acute exercise regulate nitric oxide formation in healthy humans.” Journal of Applied Physiology 82.3 (1997): 760-764.

Liu, Chunhui, et al. “Endothelial Nitric Oxide Synthase Polymorphisms and Erectile Dysfunction: A Meta‐Analysis.” The journal of sexual medicine (2015).

Liu, Donald, et al. “UVA irradiation of human skin vasodilates arterial vasculature and lowers blood pressure independently of nitric oxide synthase.” Journal of Investigative Dermatology 134.7 (2014): 1839-1846.

MacMicking, John, Qiao-wen Xie, and Carl Nathan. “Nitric oxide and macrophage function.” Annual review of immunology 15.1 (1997): 323-350.

Mani, Shailaja K., et al. “Nitric oxide mediates sexual behavior in female rats.” Proceedings of the National Academy of Sciences 91.14 (1994): 6468-6472.

Stamler, Jonathan S., et al. “Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans.” Circulation 89.5 (1994): 2035-2040.

Toda, Noboru, Kazuhede Ayajiki, and Tomio Okamura. “Nitric oxide and penile erectile function.” Pharmacology & therapeutics 106.2 (2005): 233-266.

Xie, Yining, et al. “Effect of long-term passive smoking on erectile function and penile nitric oxide synthase in the rat.” The Journal of urology 157.3 (1997): 1121-1126.

Yun, H. Y., V. L. Dawson, and T. M. Dawson. “Nitric oxide in health and disease of the nervous system.” Molecular psychiatry 2.4 (1997): 300-310.

Blackman, Marc R., et al. “Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial.” Jama 288.18 (2002): 2282-2292.

Boesen, Anders Ploug, et al. “Effect of growth hormone on aging connective tissue in muscle and tendon: gene expression, morphology, and function following immobilization and rehabilitation.” Journal of Applied Physiology 116.2 (2014): 192-203.

Carroll, Paul V., et al. “Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review.” The Journal of Clinical Endocrinology & Metabolism 83.2 (1998): 382-395.

Corpas, Emiliano, S. Mitchell Harman, and Marc R. Blackman. “Human growth hormone and human aging.” Endocrine reviews 14.1 (1993): 20-39.

Friedman, Seth D., et al. “Growth Hormone–Releasing Hormone Effects on Brain γ-Aminobutyric Acid Levels in Mild Cognitive Impairment and Healthy Aging.” JAMA neurology 70.7 (2013): 883-890.

Melmed, Shlomo. “Idiopathic adult growth hormone deficiency.” The Journal of Clinical Endocrinology & Metabolism 98.6 (2013): 2187-2197.

Holloway, L. E. A. H., et al. “Effects of recombinant human growth hormone on metabolic indices, body composition, and bone turnover in healthy elderly women.” The Journal of Clinical Endocrinology & Metabolism 79.2 (1994): 470-479.

Nyberg, Fred, and Mathias Hallberg. “Growth hormone and cognitive function.” Nature Reviews Endocrinology 9.6 (2013): 357-365.

Rudman, D., et al. “Effects of human growth hormone on body composition in elderly men.” Hormone Research in Paediatrics 36.Suppl. 1 (1991): 73-81.

Van Dam, P. S., et al. “Growth hormone, insulin-like growthfactor I and cognitive function in adults.” Growth Hormone & IGF Research 10 (2000): S69-S73.

Yalow, Rosalyn S., et al. “Plasma insulin and growth hormone levels in obesity and diabetes.” Annals of the New York Academy of Sciences 131.1 (1965): 357-373.

Alpert, Jonathan E., and Maurizio Fava. “Nutrition and depression: the role of folate.” Nutrition Reviews 55.5 (1997): 145-149.

Andrès, Emmanuel, et al. “Vitamin B12 (cobalamin) deficiency in elderly patients.” Canadian Medical Association Journal 171.3 (2004): 251-259.

Bottiglieri, T. E. O. D. O. R. O., RICHARD F. Crellin, and EDWARD H. Reynolds. “Folate and neuropsychiatry.” Folate in health and disease 1995 (1995): 435-462.

Bottiglieri, Teodoro. “Folate, vitamin B12, and neuropsychiatric disorders.” Nutrition reviews 54.12 (1996): 382-390.

Calvaresi, Eva, and Janet Bryan. “B Vitamins, Cognition, and Aging A Review.” The Journals of Gerontology Series B: Psychological Sciences and Social Sciences 56.6 (2001): P327-P339.

Fenech, Michael, Clare Aitken, and Josephine Rinaldi. “Folate, vitamin B12, homocysteine status and DNA damage in young Australian adults.” Carcinogenesis 19.7 (1998): 1163-1171.

Fioravanti, M., et al. “Low folate levels in the cognitive decline of elderly patients and the efficacy of folate as a treatment for improving memory deficits.” Archives of gerontology and geriatrics 26.1 (1997): 1-13.

Herrmann, Markus, et al. “Altered vitamin B12 status in recreational endurance athletes.” International journal of sport nutrition and exercise metabolism 15.4 (2005): 433-441.

Madhaiyan, Kalaipriya, et al. “Vitamin B< sub> 12</sub> loaded polycaprolactone nanofibers: A novel transdermal route for the water soluble energy supplement delivery.” International journal of pharmaceutics 444.1 (2013): 70-76.

Manore, Melinda M. “Effect of physical activity on thiamine, riboflavin, and vitamin B-6 requirements.” The American journal of clinical nutrition 72.2 (2000): 598s-606s.

Mohajeri, M. Hasan, Barbara Troesch, and Peter Weber. “Inadequate supply of vitamins and DHA in the elderly: implications for brain aging and Alzheimer’s type dementia.” Nutrition (2014).

Rozgony, Nancy R., et al. “Vitamin B12 Deficiency is Linked with Long-Term Use of Proton Pump Inhibitors in Institutionalized Older Adults: Could a Cyanocobalamin Nasal Spray be Beneficial?.” Journal of Nutrition for the Elderly 29.1 (2010): 87-99.

Salimi, Anayatollah, Behzad Sharif Makhmal Zadeh, and Eskandar Moghimipour. “Preparation and Characterization of Cyanocobalamin (Vit B12) Microemulsion Properties and Structure for Topical and Transdermal Application.” Iranian journal of basic medical sciences 16.7 (2013): 865.

Stabler, Sally P. “Vitamin B12 deficiency.” New England Journal of Medicine 368.2 (2013): 149-160.

Yang, Ye, Haripriya Kalluri, and Ajay K. Banga. “Effects of Chemical and Physical Enhancement Techniques on Transdermal Delivery of Cyanocobalamin (Vitamin B12) In Vitro.” Pharmaceutics 3.3 (2011): 474-484.

Bilezikian, John P., et al. “Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency.” New England Journal of Medicine 339.9 (1998): 599-603.

Boloña, Enrique R., et al. “Testosterone use in men with sexual dysfunction: a systematic review and meta-analysis of randomized placebo-controlled trials.” Mayo Clinic Proceedings. Vol. 82. No. 1. Elsevier, 2007.

Chrubasik, Julia E., et al. “A comprehensive review on the stinging nettle effect and efficacy profiles. Part II: urticae radix.” Phytomedicine 14.7 (2007): 568-579.

D’Aniello, A., et al. “D-Aspartic Acid Regulates the Release and Synthesis of LH and Testosterone in Human” The Lancet (2008). Accepted Manscript.

Eisenberg, Michael L., et al. “Testosterone Therapy and Cancer Risk.” BJU international (2014).

Fischer, M., Wilbert, D.. “Wirkprüfung eines Phytopharmakons zur Behandlung der benignen Prostatahyperplasie (BPH).” In: Rutishauser, G. (Ed.), Benigne Prostatahyperplasie III. In: Klinische und Experimentelle Urologie, vol. 22 (1992). W Zuckswerdt, New York, pp. 79–84

Godard, Michael P., Brad A. Johnson, and Scott R. Richmond. “Body composition and hormonal adaptations associated with forskolin consumption in overweight and obese men.” Obesity Research 13.8 (2005): 1335-1343.

Gouras, Gunnar K., et al. “Testosterone reduces neuronal secretion of Alzheimer’s β-amyloid peptides.” Proceedings of the National Academy of Sciences 97.3 (2000): 1202-1205.

Incledon, T. “The chronic effects of androst-4-ene-3, 6, 17-trione on endocrine responses in resistance-trained men.” Journal of the American Dietetic Association 103 (2003): 38-39.

Lombardi, G., et al. “Estrogens and health in males.” Molecular and cellular endocrinology 178.1 (2001): 51-55.

Nahata, A., and V. K. Dixit. “Ameliorative effects of stinging nettle (Urtica dioica) on testosterone‐induced prostatic hyperplasia in rats.” Andrologia 44.s1 (2012): 396-409.

Shamloul, Rany. “Natural aphrodisiacs.” The journal of sexual medicine 7.1pt1 (2010): 39-49.

Thakurdesai, Prasad A., et al. “Effects Of Glycosides Based Fenugreek Seed Extract On Serum Testosterone Levels Of Healthy Sedentary Male Subjects: A Exploratory Double Blind, Placebo Controlled, Crossover Study.” Asian Journal of Pharmaceutical and Clinical Research 7.3 (2014).

Toung, Thomas JK, Richard J. Traystman, and Patricia D. Hurn. “Estrogen-mediated neuroprotection after experimental stroke in male rats.” Stroke 29.8 (1998): 1666-1670.

Traish, A. M., et al. “Long‐term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long‐term registry study.” International journal of clinical practice 68.3 (2014): 314-329.

Wang, Christina, et al. “Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men.” The Journal of Clinical Endocrinology & Metabolism 89.5 (2004): 2085-2098.

Barger, Jamie L., et al. “A low dose of dietary resveratrol partially mimics caloric restriction and retards aging parameters in mice.” PloS one 3.6 (2008): e2264.

Baur, Joseph A., et al. “Resveratrol improves health and survival of mice on a high-calorie diet.” Nature 444.7117 (2006): 337-342.

Bhullar, Khushwant S., and Basil P. Hubbard. “Lifespan and healthspan extension by resveratrol.” Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1852.6 (2015): 1209-1218.

Bisht, Kavita, Karl-Heinz Wagner, and Andrew C. Bulmer. “Curcumin, resveratrol and flavonoids as anti-inflammatory, cyto-and DNA-protective dietary compounds.” Toxicology 278.1 (2010): 88-100.

Brasnyó, Pál, et al. “Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients.” British Journal of Nutrition 106.03 (2011): 383-389.

Bujanda, Luis, et al. “Resveratrol inhibits nonalcoholic fatty liver disease in rats.” BMC gastroenterology 8.1 (2008): 40.

Faghihzadeh, Forouzan, et al. “Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease.” Nutrition Research 34.10 (2014): 837-843.

Ghanim, Husam, et al. “A resveratrol and polyphenol preparation suppresses oxidative and inflammatory stress response to a high-fat, high-carbohydrate meal.” The Journal of Clinical Endocrinology & Metabolism 96.5 (2011): 1409-1414.

Ghanim, Husam, et al. “An antiinflammatory and reactive oxygen species suppressive effects of an extract of Polygonum cuspidatum containing resveratrol.” The Journal of Clinical Endocrinology & Metabolism 95.9 (2010): E1-E8.

Gupta, Subash C., et al. “Chemosensitization of tumors by resveratrol.” Annals of the New York Academy of Sciences 1215.1 (2011): 150-160.

Huang, Fang, et al. “Resveratrol reverses multidrug resistance in human breast cancer doxorubicin-resistant cells.” Experimental and therapeutic medicine 7.6 (2014): 1611-1616.

Jang, Meishiang, et al. “Cancer chemopreventive activity of resveratrol, a natural product derived from grapes.” Science 275.5297 (1997): 218-220.

Kennedy, David O., et al. “Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: a double-blind, placebo-controlled, crossover investigation.” The American journal of clinical nutrition 91.6 (2010): 1590-1597.

Kim, Tae Hyung, et al. “Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.” Biochimica et Biophysica Acta (BBA)-General Subjects 1840.1 (2014): 615-625.

Kundu, Joydeb Kumar, and Young-Joon Surh. “Cancer chemopreventive and therapeutic potential of resveratrol: mechanistic perspectives.” Cancer letters 269.2 (2008): 243-261.

Lagouge, Marie, et al. “Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α.” Cell 127.6 (2006): 1109-1122.

Lagouge, Marie, et al. “Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α.” Cell 127.6 (2006): 1109-1122.

Leikert, Jürgen F., et al. “Red wine polyphenols enhance endothelial nitric oxide synthase expression and subsequent nitric oxide release from endothelial cells.” Circulation 106.13 (2002): 1614-1617.

Pearson, Kevin J., et al. “Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span.” Cell metabolism 8.2 (2008): 157-168.

Shang, Jing, et al. “Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase.” Acta Pharmacologica Sinica 29.6 (2008): 698-706.

Shukla, Yogeshwer, and Richa Singh. “Resveratrol and cellular mechanisms of cancer prevention.” Annals of the New York Academy of Sciences 1215.1 (2011): 1-8.

Singh, Chandra K., Mary A. Ndiaye, and Nihal Ahmad. “Resveratrol and cancer: Challenges for clinical translation.” Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1852.6 (2015): 1178-1185.

Smoliga, James M., Joseph A. Baur, and Heather A. Hausenblas. “Resveratrol and health–a comprehensive review of human clinical trials.” Molecular nutrition & food research 55.8 (2011): 1129-1141.

Timmers, Silvie, et al. “Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans.” Cell metabolism 14.5 (2011): 612-622.

Walle, Thomas. “Bioavailability of resveratrol.” Annals of the New York Academy of Sciences 1215.1 (2011): 9-15.

Wallerath, Thomas, et al. “A blend of polyphenolic compounds explains the stimulatory effect of red wine on human endothelial NO synthase.” Nitric Oxide 12.2 (2005): 97-104.

Wallerath, Thomas, et al. “Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase.” Circulation 106.13 (2002): 1652-1658.

Wong, R. H. X., et al. “Acute resveratrol supplementation improves flow-mediated dilatation in overweight/obese individuals with mildly elevated blood pressure.” Nutrition, Metabolism and Cardiovascular Diseases 21.11 (2011): 851-856.

Griffith, RichardS, et al. “Success of L-lysine therapy in frequently recurrent herpes simplex infection.” Dermatology 175.4 (1987): 183-190

Wood, J. M., et al. “Senile hair graying: H2O2-mediated oxidative stress affects human hair color by blunting methionine sulfoxide repair.” The FASEB Journal 23.7 (2009): 2065-2075.

Alekseeva, S. V., et al. “[An experimental study of the anti-inflammatory action of Noopept and its effect on the level of cytokines].” Eksperimental’naia i klinicheskaia farmakologiia 75.9 (2011): 25-27.

Barwell, C. J., et al. “Deamination of hordenine by monoamine oxidase and its action on vasa deferentia of the rat.” Journal of pharmacy and pharmacology 41.6 (1989): 421-423. Boiko, S. S., et al. “Bioaccessibility of the new dipeptide nootropic drug Noopept.” Pharmaceutical Chemistry Journal 38.12 (2004): 645-647.

Camps, Pelayo, et al. “New tacrine-huperzine A hybrids (huprines): highly potent tight-binding acetylcholinesterase inhibitors of interest for the treatment of Alzheimer’s disease.” Journal of medicinal chemistry 43.24 (2000): 4657-4666.

Fenzl, E., et al. “Long-term study concerning tolerance and efficacy of vinpocetine in elderly patients suffering from a mild to moderate organic psychosyndrome.” Senile Dementias: Early Detection. Szerk.: Bes A. et al.: John Libbey Eurotext (1986): 580-585.

Grandt, R., et al. “Vinpocetine pharmacokinetics in elderly subjects.” Arzneimittel-Forschung 39.12 (1989): 1599-1602.

Gudasheva, T. A., et al. “Peptide analogs of piracetam as ligands of presumptive nootrope receptors.”Khim.-Farm. Zh. 11 (1985): 1322–1329.

Halliday, R., E. Callaway, and R. Lannon. “The effects of clonidine and Yohimbine on human information processing.” Psychopharmacology 99.4 (1989): 563-566.

Jeon, Kye-Im, et al. “Vinpocetine inhibits NF-κB–dependent inflammation via an IKK-dependent but PDE-independent mechanism.” Proceedings of the National Academy of Sciences 107.21 (2010): 9795-9800.

Jha, M. K., M. H. Rahman, and Hasib Sheikh. “Vinpocetine: a smart drug and a smart nutrient: a review.” IJPSR 3.2 (2012): 346-352.

Jia, Xueen, et al. “Neuroprotective and nootropic drug Noopept rescues α-synuclein amyloid cytotoxicity.” Journal of molecular biology 414.5 (2011): 699-712.

Kiss, B., and E. Karpati. “[Mechanism of action of Vinpocetine].” Acta Pharmaceutica Hungarica 66.5 (1996): 213-224.

Kovalenko, L. P., et al. “[Anti-inflammatory properties of Noopept (dipeptide nootropic agent GVS-111)].” Eksperimental’naia i klinicheskaia farmakologiia 65.2 (2001): 53-55.

Lohmann, A., et al. “Bioavailability of vinpocetine and interference of the time of application with food intake.” Arzneimittel-Forschung 42.7 (1992): 914-917.

Luo, YiFan, et al. “Solid lipid nanoparticles for enhancing vinpocetine’s oral bioavailability.” Journal of controlled release 114.1 (2006): 53-59.

Medina, Alexandre E. “Vinpocetine as a potent antiinflammatory agent.” Proceedings of the National Academy of Sciences 107.22 (2010): 9921-9922.

Medina, Alexandre E. “Vinpocetine as a potent antiinflammatory agent.” Proceedings of the National Academy of Sciences 107.22 (2010): 9921-9922.

Neznamov, G. G., and E. S. Teleshova. “Comparative studies of Noopept and piracetam in the treatment of patients with mild cognitive disorders in organic brain diseases of vascular and traumatic origin.” Neuroscience and behavioral physiology 39.3 (2009): 311-321.

Ostrovskaia, R. U., et al. “[On the mechanism of Noopept action: decrease in activity of stress-induced kinases and increase in expression of neutrophines].” Eksperimental’naia i klinicheskaia farmakologiia 73.12 (2010): 2-5.

Ostrovskaia, R. U., et al. “[The original novel nootropic and neuroprotective agent Noopept].” Eksperimental’naia i klinicheskaia farmakologiia 65.5 (2001): 66-72.

Ostrovskaya, R. U., A. P. Belnik, and Z. I. Storozheva. “Noopept efficiency in experimental Alzheimer disease (cognitive deficiency caused by β-amyloid25–35 injection into Meynert basal nuclei of rats).” Bulletin of experimental biology and medicine 146.1 (2008b): 77-80.

Ostrovskaya, R. U., A. P. Belnik, and Z. I. Storozheva. “Noopept efficiency in experimental Alzheimer disease (cognitive deficiency caused by β-amyloid₂₅₋ ₃₅ injection into Meynert basal nuclei of rats).” Bulletin of experimental biology and medicine. Bi︠︡ulletenʹ ėksperimentalʹnoĭ biologii i medit︠︡siny (2008c).

Ostrovskaya, R. U., et al. “Efficiency of Noopept in Streptozotocin-Induced Diabetes in Rats.” Bulletin of experimental biology and medicine 154.3 (2013): 334-338.

Ostrovskaya, R. U., et al. “Noopept stimulates the expression of NGF and BDNF in rat hippocampus.” Bulletin of experimental biology and medicine 146.3 (2008a): 334-337.

Ostrovskaya, Rita U., et al. “The nootropic and neuroprotective proline-containing dipeptide Noopept restores spatial memory and increases immunoreactivity to amyloid in an Alzheimer’s disease model.” Journal of Psychopharmacology 21.6 (2007): 611-619.

Qian, Bo-Chu, et al. “Pharmacokinetics of tablet huperzine A in six volunteers.” Zhongguo yao li xue bao= Acta pharmacologica Sinica 16.5 (1995): 396-398.

Romanova, G. A., et al. “Effects of Noopept in the photochemically induced stroke model.” Biopolymers. Vol. 71. No. 3. 111 RIVER ST, HOBOKEN, NJ 07030 USA: JOHN WILEY & SONS INC, 2003.

Romanova, G. A., et al. “P. 5.072 Memory restoring and neuroprotective effects of dipeptide Noopept in a photochemical stroke model.” European Neuropsychopharmacology 15 (2005): S241.

Smith, Andrew, et al. “Caffeine and central noradrenaline: effects on mood, cognitive performance, eye movements and cardiovascular function.” Journal of Psychopharmacology 17.3 (2003): 283-292.

Szakács, Tünde, Zsuzsa Veres, and László Vereczkey. “In vitro-in vivo correlation of the pharmacokinetics of vinpocetine.” Polish journal of pharmacology 53.6 (2001): 623-628.

Us, K. S., S. A. Gavrilova, and V. B. Koshelev. “P. 5.066 Neuroprotective properties of the novelnootropic dipeptide Noopept (GVS-111) on the model of severe brain ischemia.” European Neuropsychopharmacology 15 (2005): S238.

Vereczkey, L., et al. “Pharmacokinetics of vinpocetine in humans.” Arzneimittel-Forschung 29.6 (1978): 957-960.

Xu, S. S., et al. “Huperzine-A in capsules and tablets for treating patients with Alzheimer disease.” Zhongguo yao li xue bao= Acta pharmacologica Sinica 20.6 (1999): 486-490.

Zangara, Andrea. “The psychopharmacology of huperzine A: an alkaloid with cognitive enhancing and neuroprotective properties of interest in the treatment of Alzheimer’s disease.” Pharmacology Biochemistry and Behavior 75.3 (2003): 675-686.

 

1 review for Alpha Male+PLUS

  1. Andre

    Amazing product 9/10 a definite must have for all males over 40yrs

Add a review